CMP Pharma
United States 38 employees Updated 9 July 2026
CMP Pharma is a finished-dose manufacturer based in United States. It appears in 8 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 1 September 2023 as VAI.
1
registered plants
1 with an FDA FEI number
8
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 1 September 2023 VAI US FDA
- 25 January 2023 NAI US FDA
- 28 June 2018 VAI US FDA
- 21 December 2016 VAI US FDA
- 11 May 2016 VAI US FDA
- 24 October 2012 VAI US FDA
- 18 March 2010 VAI US FDA
- 17 March 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Farmville, United States | 1050589 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 8 | 1 |
Comparing suppliers?
Choose your molecules and target markets. CMP Pharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 1 September 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates